A Competitive Analysis of the Global Asthma and COPD Therapeutics Market

A Competitive Analysis of the Global Asthma and COPD Therapeutics Market

Novel Inhaler Devices and Formulations are Impetuses for Growth

RELEASE DATE
30-Oct-2014
REGION
North America
Research Code: MA2A-01-00-00-00
SKU: LS00101-NA-MR_16942
AvailableYesPDF Download
$3,950.00
In stock
SKU
LS00101-NA-MR_16942
$3,950.00
DownloadLink
ENQUIRE NOW

Description

The research service assesses marketed and investigational products, as well as combination regimens, for asthma and chronic obstructive pulmonary disease (COPD). Segmentation by drug class is provided along with additional supporting information such as clinical trial timelines and results, historical and projected launch timelines, and epidemiology. The marketed and pipeline products are broadly segmented into bronchodilators, anti-inflammatories, and combination therapies of current global interest. Novel inhaler devices, formulations, and anti-inflammatories are key drivers for the market.

Table of Contents

Key Findings

Key Findings—Asthma

Key Findings—COPD

Overview of Product Launches and Pipeline Development

Key Companies to Watch

CEO’s Perspective

Methodology and Scope

Market Overview—Segmentation

Market Overview—Definitions

Prevalence of Asthma by Country/Region

Prevalence of COPD by Country/Region

Asthma Therapeutics Market—Marketed and Pipeline Products

Asthma Therapeutics Market—Marketed and Pipeline Products (continued)

Asthma Therapeutics Market—Key Marketed Product Synopsis

Asthma Therapeutics Market—Key Marketed Product Synopsis (continued)

Asthma Therapeutics Market—Key Pipeline Product Synopsis

Asthma Therapeutics Market—Key Pipeline Product Synopsis (continued)

COPD Therapeutics Market—Marketed and Pipeline Products

COPD Therapeutics Market—Marketed and Pipeline Products (continued)

COPD Therapeutics Market—Key Marketed Product Synopsis

COPD Therapeutics Market—Key Marketed Product Synopsis (continued)

COPD Therapeutics Market—Key Pipeline Product Synopsis

COPD Therapeutics Market—Key Pipeline Product Synopsis (continued)

Total Asthma and COPD Therapeutics Market—Projected Launch Timeline for Key Pipeline Drugs

Pivotal Phase 3 Trials

Estimated Product Launch Timeline—Striverdi Respimat for Asthma and COPD by Boehringer Ingelheim

Estimated Product Launch Timeline—Quilizumab for Asthma by Genentech

Estimated Product Launch Timeline—DuoResp Spiromax for Asthma and COPD by Teva Pharmaceuticals

Estimated Product Launch Timeline—Incruse Ellipta (umeclidinium) for COPD by GSK

Estimated Product Launch Timeline—Benralizumab for Asthma by AstraZeneca

Patent Expiration Timeline

Seebri Breezhaler by Novartis

Advair/Seretide by GSK

Xolair by Genentech and Novartis

Asmanex Twisthaler by Merck & Co.

Spiriva by Boehringer Ingelheim

AirFlu Sal/Forspiro by Sandoz (Novartis)

Incruse Ellipta by GSK

Benralizumab by AstraZeneca

Bosatria by GSK

PT003 by Pearl Therapeutics (AstraZeneca)

Conclusions

Legal Disclaimer

Decision Support Database—Global Prevalence of Smokers

Decision Support Database—Global Prevalence of Smokers (continued)

Decision Support Database—Population with COPD

Decision Support Database—Population with COPD (continued)

The Frost & Sullivan Story

Value Proposition: Future of Your Company & Career

Global Perspective

Industry Convergence

360º Research Perspective

Implementation Excellence

Our Blue Ocean Strategy

Related Research
This market insight provides a first-of-its-kind analysis of market sizing and revenue forecasts through 2016 for the prevalent Ebola virus. The number of people infected nears 10,000 globally, and the Centers for Disease Control and Prevention (CDC) and World Health Organization (WHO) have deemed this the worst outbreak due to the death toll nearing 5,000. The Ebola market is segmented by diagnostics and pharmaceuticals, and the diagnostics market includes both molecular methods and immunodiagnostics tests, of which a 2-year potential-revenue forecast is provided. Molecular methods will see wide adoption for the specificity, sensitivity, and rapidity of the tests. Competitive landscape and companies to watch chapters are provided.
More Information
No Index No
Podcast No
Author Sriram Radhakrishnan
WIP Number MA2A-01-00-00-00
Is Prebook No